This website is intended for Medical Professionals only. By using this site you confirm that you are a healthcare professional.

News
Be extra vigilant about heart attack ... Health systems should warn high risk patients by smartphone when ... (17 May 2018)
CrossFit improves how people with type 2 ... New research published in Experimental Physiology has suggested ... (17 May 2018)
Keep saying yes to fish twice a week for ... A new scientific advisory reaffirms the American Heart ... (17 May 2018)
Imaging Breast Implant Rupture Dr Pierre Vassallo - Breast augmentation is the most common form ... (18 May 2018)
The 39th World Medical & Health Games ... Sports Director Pierre Chicco talks Medigames with TheSynapse. ... (18 May 2018)
Monday, 14 May 2018 20:18

Osteoporosis Drug May Benefit Heart Health Featured

Rate this item
(0 votes)

The osteoporosis drug alendronate was linked with a reduced risk of cardiovascular death, heart attack, and stroke in a Journal of Bone and Mineral Research study of patients with hip fractures. The association was seen for up to 10 years after fracture.

In the study, patients newly diagnosed with hip fracture from 2005 through 2013 were followed until late 2016. Among 34,991 patients, 4602 (13%) received osteoporosis treatment during follow-up.

Alendronate was associated with 67% and 45% lower risks of one-year cardiovascular death and heart attack, respectively. It was associated with an 18% reduced risk of stroke within five years and a 17% reduced risk of stroke within 10 years. Protective effects were not evident for other classes of osteoporosis treatments.

“It is well established that there is a world-wide crisis in the treatment of osteoporosis, due to patients’ awareness of the extremely rare side effects,” said senior author Dr. Ching-Lung Cheung, of the University of Hong Kong. “Our findings show that alendronate is potentially cardioprotective in hip fracture patients. Therefore, physicians should consider prescribing alendronate or other nitrogen-containing bisphosphonates to hip fracture patients soon after their fracture, and patients should also have good compliance with alendronate treatment, as this is not only good for your bones, but also your heart.”

In addition to clinical management, the study also has important implications in clinical trial design of anti-osteoporosis medications. The US Food and Drug Administration recently requested more data before reaching a decision on whether to approve the osteoporosis drug romosozumab, due to excess cardiovascular adverse events in the romosozumab arm compared with the alendronate arm. “In light of these important deliberations, our results suggest that such differences in cardiovascular adverse events could be potentially related to a protective association of alendronate, rather than an increase in cardiovascular adverse events related to romosozumab use, said Dr. Cheung.”


Source: Wiley
Full bibliographic information

Chor-Wing Sing, Angel YS Wong, Douglas P Kiel, Elaine YN Cheung, Joanne KY Lam, Tommy T Cheung, Esther W Chan, Annie WC Kung, Ian CK Wong and Ching-Lung Cheung. Association of Alendronate and Risk of Cardiovascular Events in Patients With Hip Fracture. Journal of Bone and Mineral Research. DOI: 10.1002/jbmr.3448. 

Read 44 times Last modified on Tuesday, 15 May 2018 18:30

TheSynapse Videos

0
0
0
0
0
0

Latest news

Highlights

  • WASP Course in Bahrain

    WASP Course, led by Prof Victor Grech and Prof Charles Savona Ventura, has recently organised a course in Bahrain. Co-hosted with Arabian Gulf University, the course, on how to write a scientific paper, focused on quantitative analysis methods and was targeted for medical doctors and allied health professionals.

    Written on April 24, 2018 Read more...

SPONSOR MESSAGE

Join

Connect with other Medical Professionals on fb in a closed facebook group

Login

Template Settings

Theme Colors

Cyan Red Green Oranges Teal

Layout

Wide Boxed Framed Rounded
Patterns for Layour: Boxed, Framed, Rounded
Top
We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…